PGS NGS 360 is based on the newest technology. Our approach ensures the best diagnostic performance among all technologies used in preimplantation diagnosis today. Sample material, cells biopsied from embryos, is unique and is integrated unprocessed with the PGS NGS 360 workflow. Consequently, any biological variation may potentially influence the test results. Thus, quality of the embryos, and further, quality of biopsied material are some of the key factors in the process.
In routine medical diagnostics, e.g. biochemical field, where sample specimen is patient’s blood, quality of the sample is strictly controlled and quantity of available sample is more than enough for many repetitions, if needed. This is definitely not the case in preimplantation genetic diagnostics. Here, sample specimen is a cell or the cells biopsied from the developing embryo.
Biopsy is an invasive procedure. Although there is no evidence that properly conducted biopsy is a threat to embryo’s viability, it is a manual procedure with the potentially case-by-case variability of outcomes. Therefore the number of biopsies from the given embryo should be reduced as much as possible. The Reproductive Medicine Societies all over the world are in agreement about this issue. Second biopsy from the same embryo should be performed only in case of the highest necessity. First conclusion: embryo biopsy material is unique.
Embryo biopsy results in one or several cells obtained for further processing. The amount of genetic material available for diagnosis is the lowest possible and it cannot be divided into several portions in case of the need to repeat the test. It is hundreds times lower than used in forensics. Second conclusion: embryo biopsy material is very unique.
Although there is a general pattern of human embryo development, every embryo develops based on its own independent dynamics and both genetics of epigenetic conditions influence on quality of embryo at each particular stage. Embryo’s quality, which is scored by the embryologists, influences the biopsied cells. Material from multiple embryos may not be similar to one another.Third conclusion: embryo biopsy material is very, very unique.
In such circumstances one would expect that degree of variation of input material will make it extremely difficult to get reliable results. For this reason, INVICTA employs the newest sequencing technology in its PGS NGS 360. Next generation sequencing is the most trustworthyl approach available on the market. It enables correction of potential sequencing errors making the technique highly accurate and reliable. NGS Post-light system used in INVICTA is simple, extremely efficient, and robust against interference or disruption. Therefore application of NGS in preimplantation diagnosis is a big advantage in comparison to other techniques, like aCGH, QF-PCR, as it provides lowest possible failure results rates.
INVICTA has the most experience in PGS NGS in the world. Up to day more than 1500 embryos has been diagnosed in clinical setting. We encourage IVF laboratories to send us material for diagnosis even if in cases of embryos that received low scores. We have rather “with hope” policy in contrast to strict “good quality embryos only” policy. For blastomere samples our data shows overall results failure to be 9.59%, including 5,95% correlated with low quality of embryos and 3.64% correlated to workflow failure. For blastocyst cells samples overall results failure is 6.08%, including 5,04% correlated with low quality of embryos and 1.04% correlated with workflow failure.
PGS NGS 360 is a high technology assay designed for very demanding input samples. The use of the next generation sequencing together with the INVICTA’s experience in PGS NGS makes it possible to achieve the lowest possible failure results rate to ensure the highest possible patient satisfaction and pregnancy rates.